Oncoinvent ASA · OSL:ONCIN
Oncoinvent ASA — Investor Presentation (April 2024)
17 slides from Oncoinvent ASA's investor presentation, April 2024
Slide 1: Oncoinvent
Oncoinvent Innovative locally acting alpha-emitter technology Lead Product Candidate: Radspherin® for Peritoneal Carcinomatosis (PC) Backed by Hadean Ventures & several high-value Family Offices in Norway, Europe
Slide 2: Oncoinvent: Differentiated, clinical stage radiopharma in multi billion market opportunity
Oncoinvent: Differentiated, clinical stage radiopharma in multi billion market opportunity Clinical stage opportunity in a rising market segment 1 Oncoinvent is currently amongst most clinically advanced radiopharma company after several big pharma M&As 1 Unique radiopharmaceutical expertise at all
Slide 3: Radiopharmaceutical Expertise at all Levels
Radiopharmaceutical Expertise at all Levels Management Scientific Founders Full BIOs available at: www.oncoinvent.com Board 3
Slide 4: In-house Production at GMP Facility
In-house Production at GMP Facility Oncoinvent has in-house 224Ra produced from 228Th, Microparticles and finished GMP Production Capability which has multiple sources goods produced in-house Current GMP facility can support the Clinical Phase 2b program. Outsourcing and scale-up required for Phase
Slide 5: Target Area - Peritoneal Carcinomatosis (PC)
Target Area - Peritoneal Carcinomatosis (PC) • Many underlying cancers types Secondary extraperitoneal origin Secondary intraperitoneal origin Lung cancer Cholangiocarcinoma • Peritoneal Metastases common at diagnosis* Breast cancer Gastric cancer • Cytoreductive Surgery is Standard of Care Malignan
Slide 6: High Unmet Medical Need
High Unmet Medical Need Long-term survival rates of patients with PC Five-year survival rates in ovarian cancer2 by disease stage of colorectal origin1 90% 78% 70% 39% 36% 24% 17% 1 year 3 year 5 year 1 2 3 4 “Historically, the survival rate for gastric carcinoma patients with peritoneal carcinomato
Slide 7: Clinical Administration of Radspherin®
Clinical Administration of Radspherin® • Radspherin® is shipped as dispersion of microparticles in a vial • Single Dose Administration of 7 Mbq through standard catheter 1-3 days after surgery to eradicate micro metastases • No incremental invasiveness or hospitalization • Can be administered bed-si
Slide 8: 224Ra alpha-emitter ideal for large body cavity surfaces
224Ra alpha-emitter ideal for large body cavity surfaces • High Radiation Energy – Effectively treating a large body cavity with minimal exposure to other organs • Shallow Radiation Depth – Limited collateral tissue damage • Convenient half-life – A 3.6-day half-life means that Radspherin® can have
Slide 9: Radspherin® - 68 patients treated in two indications
Radspherin® - 68 patients treated in two indications - Phase 1/2a fully recruited and first interim readout completed • Two Phase 1/2a studies - assessing dose, safety and tolerability, dosimetry and signal of efficacy of intraperitoneal Radspherin® • Oslo/Norway(PI: Yun Wang) RAD-18-001: Ovarian/fa
Slide 10: Radspherin® is safe and well tolerated – reduced radiation exposure to organs vs systemic treatment
Radspherin® is safe and well tolerated – reduced radiation exposure to organs vs systemic treatment • So far, in patients that have finished the follow up period, no dose limiting Well tolerated and considered safe to use toxicities were observed, no deaths, no serious adverse events related to Rads
Slide 11: Absorbed Radiation Doses to Normal Organs are low
Absorbed Radiation Doses to Normal Organs are low - Calculated doses well below known limiting thresholds • None of the patients received absorbed doses higher than 1 Gy* for any normal organ • Biokinetic modelling resulted in highest uptake values for bone, blood, kidneys and liver • Highest absorb
Slide 12: Efficacy - Data indicates substantial DFS Improvement
Efficacy - Data indicates substantial DFS Improvement - Interim efficacy analysis phase 1/2a in CRC (n=22 all dose levels) Disease-free survival at 18 months with 7 MBq Radspherin® in combination with SOC was 67 % (n=12) Local disease-free survival: No local recurrencies Overall disease-free surviva
Slide 13: Development timeline and funding required
2024 2025 2026 2027 2028 2029 2030 Funding $ 10 M per year Op. Cost. Each Phase 2b trial $ 10 M. TT cost ca. $ 10 M → $ 50-60 M to reach Phase 3 required: Full Full Milestones: 12m CRC OC Interim Full Conditional Full Ph2a Ph2a Ph2a Ph2b Ph2b Appr. OC? Ph3 Ph1/Ext OC N=11 Follow-up Ovarian IND Ph2b
Slide 14: High addressable patient numbers and unmet medical need
High addressable patient numbers and unmet medical need Ovarian Cancer USA Europe Total Colorectal Cancer USA Europe Total Patient Diagnosed (100%) 22,000 63,000 85,000 Patient Diagnosed Stage IV (100%) 39,000 113,000 152,000 Peritoneal Mets (75%) 17,000 47,000 64,000 Peritoneal Mets (25%) 10,000 28
Slide 15: Addressing a multi billion dollar market opportunity
Addressing a multi billion dollar market opportunity • Targeted Patient Population: Up to 68,000 eligible patients per year (US & Europe) • Average Pricing Estimate: $100,000 per treatment (conservative vs. benchmarks) • The total addressable market in the US and Europe alone is up to $7 billion • I
Slide 16: Key Intellectual Property
Key Intellectual Property 16
Slide 17: Oncoinvent: Differentiated, clinical stage radiopharma in multi billion market opportunity
Oncoinvent: Differentiated, clinical stage radiopharma in multi billion market opportunity Clinical stage opportunity in a rising market segment 1 Oncoinvent is currently amongst most clinically advanced radiopharma company after several big pharma M&As 1 Unique radiopharmaceutical expertise at all